Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

36

Revenue 2017

Xtandi

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Xtandi was produced by Astellas.

Merck puts prostate cancer firmly in Keytruda’s sights

Merck puts prostate cancer firmly in Keytruda’s sights

not yet approved for prostate cancer but making its way through late-stage testing – as well as chemotherapy with docetaxel and prednisone, and hormone therapy with Astellas/Pfizer’s Xtandi (enzalutamide) ... Meanwhile, the chemotherapy combination

Drug launches to watch in 2019

Drug launches to watch in 2019 Analysts believe the drug could achieve peak sales of around $1.7bn, but will face fierce competition from the likes of Pfizer and Astellas’ established Xtandi. ... It also gives J&J a leg-up in what looks set to be a big market tussle with Pfizer and

J&J’s Erleada cleared for early prostate cancer in Europe

J&J’s Erleada cleared for early prostate cancer in Europe Xtandi has also been approved for nmCRPC in the US, so the two drugs will now have to thrash it out head to head in two major geographies. ... Pfizer said the split of revenues it recorded for Xtandi in the period included a “relatively modest”

Generic threat looms to J&J’s blockbuster Zytiga in US

Generic threat looms to J&J’s blockbuster Zytiga in US Pfizer’s rival CRPC therapy Xtandi (enzalutamide) could also come under pressure form the entry of low-cost competitors.

Reference price bill tabled in US House and Senate

Reference price bill tabled in US House and Senate savings for several other drugs including Pfizer’s hormone replacement therapy Premarin (conjugated oestrogens),   Merck &Co’s Januvia (sitagliptin) for diabetes, and Astellas/Pfizer’s prostate cancer therapy Xtandi (enzalutamide).

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics